PYPD

6.1206.56%
IK

Itzhak Krinsky

Independent Non-Employee Director

Dr. Itzhak Krinsky, Ph. D. serves as Managing Director of Trenwith Securities, LLC. Dr. Krinsky served as a Director at Kamada Ltd. since November 2017 until November 14, 2019. Dr. Krinsky has broad-based expertise in the pharmaceutical industry, extensive experience in investment banking and a distinguished academic career in finance and business economics. He is Director of Apotex Health Corp. since April 1, 2023. He served as an Executive Vice President and Head of Corporate Business Development at Teva Pharmaceutical Industries Limited. He served as Vice President of Corporate Development at Teva Pharmaceutical Industries Limited since May 2005. Dr. Krinsky was Senior Executive of Special Assignments at Teva Pharmaceutical Industries Ltd. from May 2016 to February 2017. He served as Chief Executive Officer of Teva South Korea at Teva Pharmaceutical Industries Limited. He served as Head of Business Development and Corporate Vice President at Teva Pharmaceutical Industries Limited and served as its Head of Business Development of Asia Pacific from October 2012 to April 2016. He served as Corporate Vice President of Business Development at Teva Pharmaceutical Industries Limited since May 2005. He serves as Independent Director of Catalent USA Woodstock, Inc. since May 2021. He has extensive global pharmaceutical, investment banking and M&A experience. He served as Managing Director of The Silverfern Group, Inc. from January 2003 to February 2005. Prior to joining Teva, he held various senior positions in investment banks in New York City including with Bankers Trust and Deutsche Bank. He served as the Managing Director of New York-based Trenwith Group LLC (now BDO Capital Advisors, LLC). Dr. Krinsky is Independent Non-Employee Director at PolyPid Ltd. since January 2019. Dr. Krinsky held numerous accomplishments at Teva included the completion of multiple transactions, most notably the acquisitions of Ivax Corporation, Barr Pharmaceuticals and RatioPharm. Before BDO Capital Advisors, LLC, he advised private equity firms, start-ups and venture funds at The Silverfern Group Inc. Before New York-based Silverfern, he served with M&A clients in the telecommunications and technology industries as Managing Director with Deutsche Bank's North American brokerage unit, Deutsche Bank Alex. Brown Inc. From July 2001 to December 2002, Dr. Krinsky served as Managing Director of I. Krinsky, Financial & Investment Consulting in New York City and from January 1998 to May 2001 and a Senior Strategist with the Investment Banking Research and Strategy Group of Bankers Trust (the predecessor of Deutsche Bank Securities). He served as a Managing Director in the Acquisition and Corporate Advisory Group of Deutsche Bank Securities in New York City. Prior to his retirement as a Senior Executive, Dr. Krinsky held multiple management-level positions at Teva Pharmaceuticals over a 12 year-period. He serves as Chairman of the Board at Teva-Handok Pharma Co., Ltd. He serves as the Director at Halo Pharma, Inc. since June 2017. Dr. Krinsky serves on the boards of multiple public and private biopharmaceutical companies. He was the Interim Chairman of Concordia International Corp. since May 31, 2018 until September 6, 2018. He served as Chairman of Teva Japan at Teva Pharmaceutical Industries Limited since October 2012 until April 2016 and served as Chairman of Teva South Korea since October 2012 until April 2016. He served as Non Executive Chairman of the Board of ERBA Diagnostics, Inc. from April 2006 to September 2008. Dr. Krinsky serves as a Member of the boards of Can-fite Biopharma Ltd. He was a Director of Concordia International Corp. since May 03, 2017 until September 6, 2018. He served as a Director of Advanced Vision Technology (A. V. T.) Ltd., from 2005 to 2007 and from July 2007 to December 2007, he served as a Member of the Board of Directors of Eldav Investment Ltd. He served as a Director of ERBA Diagnostics, Inc. from April 2006 to September 02, 2008. His academic career includes a position as Professor of Finance & Business Economics, Michael G. DeGroote School of Business, McMaster University, Canada and as a Visiting Professor in Institute for International Studies and Training of Japan, Kamiide, Japan, Nankai University, Tianjin The Peoples Republic of China and the Leonard N. Stern School of Business at New York University as well as extensive publications in leading academic journals. In 2014, he was named by SCRIP as one of the top 100 Global Leaders in the Pharmaceutical Industry. He has published more than 80 articles in leading peer reviewed academic journals. Dr. Krinsky holds a B. A. and M. A. in Economics from Tel Aviv University in 1976 and 1978, respectively and a Ph. D. in Economics from McMaster University in 1983.

Positions